Press Releases

• Progress in the colorectal and lung cancer study; partner starts HIV study with lead product MGN1703
• Cash inflow of € 28.3 million following capital increase
• Forecast for 2015 financial year confirmed
• Dr. Mariola...

At yesterday’s Annual General Meeting of the biotechnology company MOLOGEN AG, Oliver Krautscheid was reelected as a member of the Supervisory Board. In addition, the Supervisory Board once again unanimously voted Oliver Krautscheid to the position...

The Supervisory Board of biotechnology company MOLOGEN AG today appointed Dr. Mariola Söhngen as Member of the Executive Board and new Chief Executive Officer (CEO) of MOLOGEN AG with effect from November 1, 2015. Dr. Söhngen is co-founder of PAION...

The biotechnology company MOLOGEN AG presented a poster on the clinical trial IMPALA with the cancer immunotherapy MGN1703 at the ESMO 17th World Congress on Gastrointestinal Cancer (WCGI) in Barcelona (July 1-4, 2015). The poster was titled...

The biotechnology company MOLOGEN AG announced today that its partner, the Danish Aarhus University Hospital, treated the first patients in the TEACH study. The collaboration started in early May 2015. Patient enrollment is expected to be completed...

The biotechnology company MOLOGEN AG will present a poster on the phase II clinical trial “IMPACT” with the cancer immunotherapy MGN1703 at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (May 29-June 2, 2015)....

Biotechnology company MOLOGEN AG made progress in the first quarter of 2015 with regard to patient recruitment for its current clinical trials with the MGN1703 immunotherapy, which is the company’s main product candidate. MOLOGEN’s quarterly report,...